Volume 63, Issue 4 pp. 481-483
Report

Racial, ethnic, and biologic sex disparities in outpatient laboratory monitoring of isotretinoin use: a cross-sectional study

Divya Manoharan BA

Corresponding Author

Divya Manoharan BA

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence

Divya Manoharan, BA

Johns Hopkins University School of Medicine

601 N Caroline Street

Baltimore, MD 21287

USA

E-mail: [email protected]

Search for more papers by this author
Nancy Nkansah-Mahaney MD, PharmD, MBA

Nancy Nkansah-Mahaney MD, PharmD, MBA

Johns Hopkins Hospital Department of Dermatology, Baltimore, MD, USA

Search for more papers by this author
Anna Chien MD

Anna Chien MD

Johns Hopkins Hospital Department of Dermatology, Baltimore, MD, USA

Search for more papers by this author
First published: 18 December 2023
Citations: 1

Conflict of interest: None.

Funding source: None.

Abstract

Background

Isotretinoin is commonly used for the treatment of acne. Despite high efficacy, isotretinoin has a side effect profile that prompts regular outpatient laboratory monitoring. Emerging evidence suggests clinically significant lab abnormalities are rare. Racial, ethnic, and biologic sex disparities in laboratory monitoring of isotretinoin have yet to be characterized.

Methods

This study explores disparities in laboratory monitoring of patients prescribed isotretinoin, factoring in the COVID-19 pandemic given its impacts on laboratory monitoring. Two populations were evaluated: all patients taking isotretinoin, and patients taking isotretinoin with no metabolic, cardiovascular, hematologic, hepatic, or renal comorbidities. The latter population was included to screen out patients who might receive increased laboratory testing for conditions besides isotretinoin use.

Results

Our data reveal that African-American, Asian, and Hispanic patients prescribed isotretinoin were more likely than Caucasian patients to receive orders for outpatient laboratory monitoring. These disparities persisted independent of comorbidities that may prompt additional testing, suggesting that non-Caucasian patients bear an additional testing burden even when their comorbidities were matched to their peers. Disparities persisted in the setting of reduced laboratory monitoring due to the COVID-19 pandemic.

Conclusions

These data reveal that patients of color are more likely to receive outpatient laboratory monitoring for isotretinoin prescriptions. There is an opportunity for testing standardization to improve medication access, decrease burden and costs for patients and the healthcare system, and decrease racial disparities in prescribing and monitoring of isotretinoin. Dermatology clinics may benefit from standard operating procedures outlining for whom regular monitoring is needed.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.